Glioma cells with CRISPR-modified NR1H2 (crLXRβ-1) expressed less ABCA1 in membrane fractions of cells at high cell density than cells modified by a non-targeting CRISPR control (crNT) (Fig. 2F). This evidence concerns the gene ABCA1 and central nervous system cancer.